Estimated reading time: 4 minutes
The treatment landscape for multiple sclerosis has evolved over the years, with advancements in research and drug development. As a complex and chronic condition, there are a number of drugs developed regularly to treat MS.
While there is no cure for MS, treatment can focus on speeding recovery after attacks. It can also slow the progression of the disease and manage symptoms. Here is a general overview of some of the key milestones in the approval of novel treatments to combat symptoms.
Betaseron (Interferon Beta-1b)
Introduced in 1993, Betaseron marked a significant milestone as one of the pioneering drugs approved for treating relapsing forms of multiple sclerosis (MS). As an interferon beta-1b formulation, Betaseron plays a crucial role in regulating the immune system. By modulating immune responses, it helps mitigate the severity and frequency of MS relapses. This injectable medication became a foundational component in the early treatment landscape, providing patients with a viable option to manage the unpredictable nature of the disease.
Copaxone (Glatiramer Acetate)
In 1996, Copaxone emerged as a groundbreaking advancement in MS treatment. Copaxone is administered as a daily injection and contains glatiramer acetate. It operates by modulating the immune response, specifically targeting inflammation associated with relapsing forms of MS. Copaxone's introduction expanded treatment options, offering patients an alternative with the potential to reduce the impact of relapses on their quality of life.
Avonex (Interferon Beta-1a)
Approved in 1996, Avonex is another variant of interferon beta-1a, contributing to the arsenal against MS relapses. This is a once a week injectable medication, and provides patients with a treatment option that aligns with their preferences and needs. Avonex, like other interferons, helps regulate the immune system, aiming to decrease the frequency and severity of MS relapses.
Rebif (Interferon Beta-1a)
In 2002, Rebif joined the ranks of interferon beta-1a formulations approved for treating relapsing forms of MS. Similar to Avonex, Rebif is administered through injections, but with a higher frequency. The availability of multiple formulations of interferon beta-1a offered patients more choices in tailoring their treatment plans. Rebif's approval further diversified the treatment landscape for MS.
Tysabri (Natalizumab)
Introduced in 2004, Tysabri represents a different approach to MS treatment as a monoclonal antibody. By targeting specific immune cells and preventing their entry into the brain, Tysabri helps reduce damage and inflammation. It is approved for relapsing forms of MS and is administered intravenously. Tysabri's approval brought a novel perspective to MS management, offering patients an option with a unique mechanism of action.
Gilenya (Fingolimod)
Gilenya, approved in 2010, stands out as an oral medication, providing an alternative to injectable treatments. This sphingosine 1-phosphate receptor modulator works by modulating the immune system, thereby reducing the frequency of relapses. The convenience of an oral formulation marked a significant advancement in MS treatment, catering to patients who may prefer or require a different mode of administration.
Tecfidera (Dimethyl Fumarate)
Tecfidera is an oral medication introduced in 2013. It is designed to decrease inflammation and disease activity in MS. As a disease-modifying therapy, Tecfidera also offers a convenient alternative for individuals seeking an oral treatment option for relapsing forms of MS. Similar to Gilenya, as an oral medication it is considerably more convenient.
Ocrevus (Ocrelizumab)
Ocrevus, a monoclonal antibody approved in 2017, addresses both relapsing and primary progressive forms of MS. By targeting specific cells in the immune system, Ocrevus helps manage the disease's progression and provides a valuable treatment option for a broader spectrum of MS patients.
Mayzent (Siponimod)
Mayzent, an oral medication approved in 2019, focuses on secondary progressive MS, slowing down disability progression. As a sphingosine 1-phosphate receptor modulator, Mayzent also helps manage the disease by reducing inflammation and disease activity, contributing to the evolving landscape of MS treatments.
Mavenclad (Cladribine)
Also approved in 2019, Mavenclad offers a unique treatment regimen for relapsing forms of multiple sclerosis. Administered in short courses over two years, Mavenclad provides an alternative approach to managing the disease. The goal of this drug is to reduce relapses and enhance long-term outcomes.
This evolving landscape underscores the importance of individualized treatment plans. Ongoing research promises additional therapeutic options for those affected by MS.
The healthcare landscape is complex. PatientsLikeMe works hard to give our members the resources and support they need in their health journey. Interested in learning more? Create a free PLM account today, and join nearly 1 million members in treating their conditions.